Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Etanercept
Enbrel
Not routinely available
NICE (TA383 (SMC 212/05))
01/07/2019

Indication

For the treatment of severe active ankylosing spondylitis.

For the treatment of severe active ankylosing spondylitis.

Therapeutic Area

Musculoskeletal and joint diseases

Status Description

Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines

Formulation

25mg vial of powder for subcutaneous injection

Comments

January 2006 - Added to the LJF, for Specialist Use only. February 2016 - NICE MTA advice: SMC advice 212/05 is superseded by NICE TA383. July 2019 (as per LJF) - Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.

Link to Advice

TA383 (SMC 212/05)

Advice Published

01/02/2016